MC0518

Phase 3Biologic

MC0518 is one of 10 biologic programs targeting Steroid-Refractory Acute Graft-Versus-Host Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Steroid-Refractory Acute Graft-Versus-Host DiseaseRecruiting

Acute Graft Versus Host DiseaseActive, not recruiting

Steroid-Refractory Acute Graft-Versus-Host DiseasePhase 3

Recruiting

Acute Graft Versus Host DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Acute Graft Versus Host Disease

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

3 2

Stelara

Johnson & Johnson

Phase 2

2 3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Phase 2

2 4

Arava

Sanofi

Phase 1

1 5

Gecacitinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2

1 6

MC0518

Mmedac GmbH

Phase 3

1 7

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 8

Inolimomab

EElsaLys Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Steroid-Refractory Acute Graft-Versus-Host Disease

NCT04629833

Q2 2031

Phase 2Active, not recruiting

Acute Graft Versus Host Disease

NCT06075706

Clinical

Trials by Indication[1]

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting·Mmedac GmbH·Phase 3·NCT04629833·210 enrolled

Acute Graft Versus Host Disease1 trial

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Active, not recruiting·Mmedac GmbH·Phase 2·NCT06075706·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MC0518. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MC0518 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MC0518. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — medac GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Mmedac GmbH

MC0518

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q2 2031

Trials by Indication[1]

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Acute Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News